JP3106265B2 - Modified lysozyme - Google Patents
Modified lysozymeInfo
- Publication number
- JP3106265B2 JP3106265B2 JP04157391A JP15739192A JP3106265B2 JP 3106265 B2 JP3106265 B2 JP 3106265B2 JP 04157391 A JP04157391 A JP 04157391A JP 15739192 A JP15739192 A JP 15739192A JP 3106265 B2 JP3106265 B2 JP 3106265B2
- Authority
- JP
- Japan
- Prior art keywords
- lysozyme
- group
- acid
- copolymer
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000010335 lysozyme Nutrition 0.000 title claims description 69
- 108010014251 Muramidase Proteins 0.000 title claims description 68
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims description 68
- 239000004325 lysozyme Substances 0.000 title claims description 68
- 229960000274 lysozyme Drugs 0.000 title claims description 68
- 102000016943 Muramidase Human genes 0.000 title claims 2
- 229920001577 copolymer Polymers 0.000 claims description 33
- -1 alkenyl ether Chemical compound 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 125000005702 oxyalkylene group Chemical group 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000000178 monomer Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 102100033468 Lysozyme C Human genes 0.000 description 66
- 230000000694 effects Effects 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 125000004018 acid anhydride group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000004327 boric acid Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000192041 Micrococcus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 102220240796 rs553605556 Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000008065 acid anhydrides Chemical group 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- FVQMJJQUGGVLEP-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy 2-ethylhexaneperoxoate Chemical compound CCCCC(CC)C(=O)OOOC(C)(C)C FVQMJJQUGGVLEP-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LMMTVYUCEFJZLC-UHFFFAOYSA-N 1,3,5-pentanetriol Chemical compound OCCC(O)CCO LMMTVYUCEFJZLC-UHFFFAOYSA-N 0.000 description 1
- PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 1
- ZONJATNKKGGVSU-UHFFFAOYSA-N 14-methylpentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCC(O)=O ZONJATNKKGGVSU-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-N 7-methyloctanoic acid Chemical compound CC(C)CCCCCC(O)=O XZOYHFBNQHPJRQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 102100026863 Lysozyme-like protein 4 Human genes 0.000 description 1
- 108050000796 Lysozyme-like protein 4 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MNLRQHMNZILYPY-MKFCKLDKSA-N N-acetyl-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MKFCKLDKSA-N 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- QXJQHYBHAIHNGG-UHFFFAOYSA-N trimethylolethane Chemical compound OCC(C)(CO)CO QXJQHYBHAIHNGG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、高分子の共重合体で修
飾された安定なリゾチームに関し、更に詳しくは、水系
中で長時間活性を持続することができ、適用範囲の広い
修飾リゾチームに関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a stable lysozyme modified with a high molecular weight copolymer, and more particularly, to a modified lysozyme which can maintain its activity in an aqueous system for a long time and has a wide range of application. .
【0002】[0002]
【従来の技術】リゾチームは、細菌細胞壁のムコペプチ
ドなどに存在するN−アセチルムラミン酸(MurNAc) と
N−アセチルグルコサミン(GlcNAc) 間のβ1→4結合
を加水分解する溶菌性酵素である。この酵素は動植物界
に広く存在しているが、その中でもニワトリ卵白リゾチ
ームが最もよく研究されている。その分子量は14,300、
129 個のアミノ酸から成る比較的小さなタンパク質であ
り、酵素として初めてX線結晶解析が行なわれ、立体構
造も明らかにされている。2. Description of the Related Art Lysozyme is a lytic enzyme that hydrolyzes the β1 → 4 bond between N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc), which is present in mucopeptides of bacterial cell walls. This enzyme is widely found in the animal and plant kingdoms, of which hen egg white lysozyme is the most studied. Its molecular weight is 14,300,
It is a relatively small protein consisting of 129 amino acids. It has been subjected to X-ray crystallography for the first time as an enzyme, and its three-dimensional structure has been clarified.
【0003】リゾチームの主な薬理作用としては (1)ウ
イルス性疾患に対する抗ウイルス作用、(2) 細菌、原虫
類感染に対する抗感染作用、(3) 止血作用、(4) 抗腫
瘍、抗炎症作用、(5) 組織修復作用などが知られてい
る。リゾチームの応用については抗ウイルス、抗感染、
組織修復作用などを化粧品として洗顔料、基礎化粧料な
どに利用する試みがあり、また、歯みがきやうがい薬に
用いて歯牙う蝕をもたらす細菌の抑制やウイルス性口内
炎の予防、口腔からの感染防止を目的とする試みがあ
る。The main pharmacological actions of lysozyme include (1) antiviral action against viral diseases, (2) antiinfective action against bacterial and protozoan infections, (3) hemostatic action, (4) antitumor and antiinflammatory actions (5) Tissue repair action is known. Lysozyme applications include anti-virus, anti-infection,
Attempts have been made to use tissue-repairing effects as cosmetics in facial cleansers, basic cosmetics, etc.In addition, it is used in toothpaste and mouthwashes to control bacteria that cause dental caries, prevent viral stomatitis, and prevent infection from the oral cavity There is an attempt for the purpose.
【0004】[0004]
【発明が解決しようとする課題】しかしながら、リゾチ
ームを直接水系中に配合すると酵素活性が低下したり、
皮膚に対して刺激やアレルギーを与えやすい等の問題が
ある。リゾチームの応用にあたっては、使用直前まで乾
燥状態におき、使用時に水溶液と混合して用いる方法
や、リポソーム化、マイクロカプセル化、更には、高分
子化合物による固定化など色々な試みがなされている
が、マイクロカプセル化による方法は、リゾチームと水
溶液等の基剤との接触を使用する直前まで断つことによ
る安定化であり、本質的な問題の解決ではない。また、
多価アルコールや、マルトース、ソルビトール等の糖類
を添加する方法は、プロテアーゼ等の他の酵素の安定化
として有効であるが、リゾチームに対してはほとんど効
果がなく、糖類の添加はかえって安定性を悪くし、その
他の方法でも充分満足のいく安定化の効果が得られてい
ない。However, when lysozyme is directly incorporated into an aqueous system, the enzyme activity decreases,
There are problems such as easy irritation and allergy to the skin. In the application of lysozyme, various attempts have been made such as leaving it in a dry state until immediately before use, mixing it with an aqueous solution at the time of use, making it into a liposome, microencapsulating it, and immobilizing it with a polymer compound. The method of microencapsulation is a stabilization by cutting off the contact between lysozyme and a base such as an aqueous solution until immediately before use, and does not solve an essential problem. Also,
The method of adding polysaccharides such as polyhydric alcohol, maltose, and sorbitol is effective for stabilizing other enzymes such as protease, but has little effect on lysozyme. However, other methods have not been able to obtain a sufficiently satisfactory stabilizing effect.
【0005】本発明は、水系中で長時間活性を持続する
ことができ、適用範囲の広い修飾リゾチームを提供する
ことを目的とする。An object of the present invention is to provide a modified lysozyme which can maintain its activity in an aqueous system for a long time and has a wide range of application.
【0006】[0006]
【課題を解決するための手段】本発明者らは、同一分子
中に酸無水物基とポリオキシアルキレン基を合わせもつ
重合体を化学的に結合させたリゾチームが、水系中でも
長時間活性を持続することを見出し、本発明に到達し
た。すなわち、本発明は式(1)で示されるアルケニル
エーテルと無水マレイン酸と他の単量体とのモル比が5
〜60:20〜90:0〜30である共重合体を化学結合した修
飾リゾチームである。Means for Solving the Problems The present inventors have found that lysozyme, in which a polymer having an acid anhydride group and a polyoxyalkylene group combined in the same molecule, is chemically bonded, has a long-lasting activity even in an aqueous system. And arrived at the present invention. That is, in the present invention, the molar ratio of the alkenyl ether represented by the formula (1), maleic anhydride and another monomer is 5%.
The modified lysozyme is obtained by chemically bonding a copolymer having a ratio of 6060: 20 to 90: 0-30.
【0007】[0007]
【化2】 Embedded image
【0008】(Zは2〜8個の水酸基を持つ化合物の残
基、AOは炭素数2〜18のオキシアルキレン基の1種ま
たは2種以上の混合物で、2種以上のときはブロック状
に付加していてもランダム状に付加していてもよく、R
1 は炭素数2〜5のアルケニル基、R2 は炭素数1〜24
の炭化水素基またはアシル基、aとbとcはオキシアル
キレン基の平均付加モル数でそれぞれ0〜600 、mは1
〜7の整数、nは0〜6の整数、m+n=1〜7、n/
(1+m+n)≦1/2、かつa+bm+cn=1〜10
00である)。(Z is a residue of a compound having 2 to 8 hydroxyl groups, AO is one or a mixture of two or more oxyalkylene groups having 2 to 18 carbon atoms. May be added at random or may be added at random.
1 represents an alkenyl group having 2 to 5 carbon atoms, and R 2 represents 1 to 24 carbon atoms.
A, b and c are each an average number of added moles of an oxyalkylene group of 0 to 600, and m is 1
An integer of 0 to 7, n is an integer of 0 to 6, m + n = 1 to 7, n /
(1 + m + n) ≦ 1 / and a + bm + cn = 1 to 10
00).
【0009】式(1)において、Zを残基とする2〜8
個の水酸基を持つ化合物としては、エチレングリコー
ル、プロピレングリコール、ブチレングリコール、ヘキ
シレングリコール、スチレングリコール、炭素数8〜18
のアルキレングリコール、ネオペンチルグリコール等の
グリコール、グリセリン、ジグリセリン、ポリグリセリ
ン、トリメチロールエタン、トリメチロールプロパン、
1,3,5−ペンタントリオール、エリスリトール、ペ
ンタエリスリトール、ジペンタエリスリトール、ソルビ
トール、ソルビタン、ソルバイド、ソルビトールとグリ
セリンの縮合物、アドニトール、アラビトール、キシリ
トール、マンニトール等の多価アルコール、あるいはそ
れらの部分エーテル化物またはエステル化物;キシロー
ス、アラビノース、リボース、ラムノース、グルコー
ス、フルクトース、ガラクトース、マンノース、ソルボ
ース、セロビオース、マルトース、イソマルトース、ト
レハロース、シュークロース、ラフィノース、ゲンチア
ノース、メレジトース等の糖、あるいはそれらの部分エ
ーテル化物またはエステル化物;カテコール、レゾルシ
ノール、ヒドロキノン、フロログルシン等のフェノール
類が挙げられる。In the formula (1), 2 to 8 wherein Z is a residue
Compounds having one hydroxyl group include ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, styrene glycol, and carbon atoms having 8 to 18 carbon atoms.
Glycols such as neopentyl glycol, glycerin, diglycerin, polyglycerin, trimethylolethane, trimethylolpropane,
Polyhydric alcohols such as 1,3,5-pentanetriol, erythritol, pentaerythritol, dipentaerythritol, sorbitol, sorbitan, sorbide, sorbitol and glycerin, adonitol, arabitol, xylitol, mannitol, and partially etherified products thereof Or an esterified product; a sugar such as xylose, arabinose, ribose, rhamnose, glucose, fructose, galactose, mannose, sorbose, cellobiose, maltose, isomaltose, trehalose, sucrose, raffinose, gentianose, melezitose, or a partially etherified product thereof, or Esters; phenols such as catechol, resorcinol, hydroquinone, and phloroglucin.
【0010】AOで示されるオキシアルキレン基として
は、オキシエチレン基、オキシプロピレン基、オキシブ
チレン基、オキシテトラメチレン基、オキシスチレン
基、オキシドデシレン基、オキシテトラデシレン基、オ
キシヘキサデシレン基、オキシオクタデシレン基等が挙
げられ、これらは1種だけ付加してもよく、2種以上が
同時に付加していてもよい。また、2種以上が同時に付
加しているときは、ブロック状付加でもランダム状付加
でもよい。The oxyalkylene group represented by AO includes oxyethylene, oxypropylene, oxybutylene, oxytetramethylene, oxystyrene, oxydecylene, oxytetradecylene, oxyhexadecylene. And an oxyoctadecylene group. These may be added alone, or two or more may be added simultaneously. When two or more types are added at the same time, block-shaped addition or random addition may be performed.
【0011】オキシアルキレン基は共重合体とリゾチー
ムとの親和性を高めるため、かつ、リゾチームの安定性
を向上させるために必要であるが、あまり多いと、共重
合体中の無水マレイン酸単位の重量割合が低くなって、
リゾチーム中のアミノ基との反応がおこりにくくなるの
で、a+bm+cnは1000を超えないことが必要であ
る。The oxyalkylene group is necessary to increase the affinity between the copolymer and lysozyme and to improve the stability of lysozyme. The weight percentage is lower,
Since the reaction with the amino group in the lysozyme hardly occurs, it is necessary that a + bm + cn does not exceed 1,000.
【0012】R1 で示される炭素数2〜5のアルケニル
基としてはビニル基、アリル基、メタリル基、1,1−
ジメチル−2−プロペニル基、3−メチル−3−ブテニ
ル基等がある。R2 で示される炭素数1〜24のアルキル
基としては、メチル基、エチル基、プロピル基、イソプ
ロピル基、ブチル基、イソブチル基、第三ブチル基、ペ
ンチル基、イソペンチル基、ヘキシル基、イソヘプチル
基、2−エチルヘキシル基、オクチル基、イソノニル
基、デシル基、ドデシル基、イソトリデシル基、テトラ
デシル基、ヘキサデシル基、イソセチル基、オクタデシ
ル基、イソステアリル基、オレイル基、オクチルドデシ
ル基、ドコシル基、デシルテトラデシル基、ベンジル
基、クレジル基、ブチルフェニル基、ジブチルフェニル
基、オクチルフェニル基、ノニルフェニル基、ドデシル
フェニル基、ジオクチルフェニル基、ジノニルフェニル
基、スチレン化フェニル基等があり、アシル基として
は、酢酸、プロピオン酸、酪酸、イソ酪酸、カプリル
酸、2−エチルヘキサン酸、イソノナン酸、カプリン
酸、ラウリン酸、ミリスチン酸、パルミチン酸、イソパ
ルミチン酸、ステアリン酸、イソステアリン酸、アラキ
ン酸、ベヘン酸、パルミトレイン酸、オレイン酸、リノ
ール酸、リノレン酸、エルカ酸、安息香酸、ヒドロキシ
安息香酸、桂皮酸、没食子酸等に由来するアシル基があ
る。The alkenyl group having 2 to 5 carbon atoms represented by R 1 includes vinyl, allyl, methallyl, 1,1-
Examples include a dimethyl-2-propenyl group and a 3-methyl-3-butenyl group. Examples of the alkyl group having 1 to 24 carbon atoms represented by R 2 include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a tert-butyl group, a pentyl group, an isopentyl group, a hexyl group, and an isoheptyl group. , 2-ethylhexyl, octyl, isononyl, decyl, dodecyl, isotridecyl, tetradecyl, hexadecyl, isocetyl, octadecyl, isostearyl, oleyl, octyldodecyl, docosyl, decyltetradecyl Group, benzyl group, cresyl group, butylphenyl group, dibutylphenyl group, octylphenyl group, nonylphenyl group, dodecylphenyl group, dioctylphenyl group, dinonylphenyl group, styrenated phenyl group, and the like.As the acyl group, Acetic acid, propionic acid, butyric acid, isobutyric acid , Caprylic acid, 2-ethylhexanoic acid, isononanoic acid, capric acid, lauric acid, myristic acid, palmitic acid, isopalmitic acid, stearic acid, isostearic acid, arachinic acid, behenic acid, palmitoleic acid, oleic acid, linoleic acid, There are acyl groups derived from linolenic acid, erucic acid, benzoic acid, hydroxybenzoic acid, cinnamic acid, gallic acid and the like.
【0013】式(1)のアルケニルエーテルと無水マレ
イン酸との共重合体がリゾチームと充分に結合するため
には、酸無水物構造が必要であり、遊離の水酸基が多い
アルケニルエーテルを用いると重合の際に酸無水物単位
とエステル結合をするために、リゾチームとの反応性が
低下したり、共重合体の溶媒への溶解性が低下したりす
るので、n/(1+m+n)≦1/2であることが必要
である。In order for the copolymer of the alkenyl ether of the formula (1) and maleic anhydride to be sufficiently bonded to lysozyme, an acid anhydride structure is required, and if an alkenyl ether having a large amount of free hydroxyl groups is used, the polymerization will proceed. In this case, since an ester bond is formed with the acid anhydride unit, the reactivity with lysozyme is reduced, or the solubility of the copolymer in the solvent is reduced. Therefore, n / (1 + m + n) ≦ 1/2 It is necessary to be.
【0014】本発明で用いる共重合体は式(1)で示さ
れるアルケニルエーテルと無水マレイン酸とをラジカル
重合触媒を用いて共重合させることによって、容易に得
ることができる。その際、更に他の単量体を加えて共重
合させても良い。他の単量体としては、アクリル酸、メ
タクリル酸、イタコン酸、クロトン酸などの不飽和カル
ボン酸、スチレン、メチルスチレンなどの芳香族ビニル
化合物、塩化ビニル、塩化ビニリデンなどのハロゲン化
ビニル化合物、イソブチレン、ジイソブチレンなどのオ
レフィン、そのほか酢酸ビニル、アクリロニトリル、ア
クリルアミドなどがある。これらは共重合体に粘着性を
持たせるなどの物性改良を行う際に加えることができる
が、その割合があまり多くなると、リゾチームの修飾に
必要なオキシアルキレン基あるいは酸無水物基の含有量
が低下し修飾がうまくできなくなるので、他の単量体の
割合が全単量体中の30モル%以下である必要がある。The copolymer used in the present invention can be easily obtained by copolymerizing the alkenyl ether represented by the formula (1) with maleic anhydride using a radical polymerization catalyst. At that time, another monomer may be added for copolymerization. Other monomers include unsaturated carboxylic acids such as acrylic acid, methacrylic acid, itaconic acid and crotonic acid, aromatic vinyl compounds such as styrene and methylstyrene, vinyl halide compounds such as vinyl chloride and vinylidene chloride, and isobutylene. And olefins such as diisobutylene, and vinyl acetate, acrylonitrile, and acrylamide. These can be added at the time of improving physical properties such as imparting tackiness to the copolymer, but if the proportion is too large, the content of oxyalkylene groups or acid anhydride groups required for lysozyme modification is reduced. The ratio of other monomers must be 30 mol% or less of the total monomers, since the concentration is lowered and modification cannot be performed well.
【0015】本発明で用いる共重合体は、重合開始剤の
種類あるいは式(1)のアルケニルエーテルの構造を変
化させることにより、種々の重合度の共重合体を得るこ
とができ、その重量平均分子量は1000〜200 万、好まし
くは3000〜10万である。またオキシアルキレン基のうち
でオキシエチレン基が多く付加したものを用いると親水
性の大きい共重合体を得ることができる。The copolymer used in the present invention can obtain copolymers having various degrees of polymerization by changing the type of polymerization initiator or the structure of the alkenyl ether of the formula (1). The molecular weight is from 10 to 2,000,000, preferably from 3000 to 100,000. In addition, a copolymer having a high hydrophilicity can be obtained by using an oxyalkylene group to which a large number of oxyethylene groups are added.
【0016】また本発明の修飾リゾチームを得る方法
は、リゾチーム中のアミノ基を利用する方法であり、対
象となるリゾチームとしてはニワトリの卵白に由来する
リゾチームをはじめ、シチメンチョウ、アヒル等の卵白
に由来するもの、また、パパイヤ、イチジク等の植物に
由来するもの、また、バチルス・スブチリス(Bacilluss
ubtilis) などの微生物に由来するものなど種々のもの
が使用できるが、特にこれらに限定されるものではな
い。The method for obtaining the modified lysozyme of the present invention is a method utilizing an amino group in the lysozyme. The target lysozyme is lysozyme derived from chicken egg white, as well as egg white such as turkey and duck. And plants derived from plants such as papaya and figs, and Bacillus subtilis (Bacilluss subtilis).
Various substances such as those derived from microorganisms such as ubtilis) can be used, but are not particularly limited thereto.
【0017】本発明の修飾リゾチームは、共重合体とリ
ゾチームとを反応させることにより得ることができる。
共重合体とリゾチームとを反応させるときの比率は、リ
ゾチーム中のアミノ基あるいは共重合体中の酸無水物基
の含有量により異なるため一概に特定することはできな
いが、アミノ基の量に比べて共重合体の量が少な過ぎる
と修飾率が低下するために目的とする経時安定性が不充
分となり、共重合体の量が多過ぎると修飾リゾチームの
初期活性が著しく低下するため、好ましい範囲は、リゾ
チーム100 重量部に対して、共重合体50〜400 重量部で
ある。The modified lysozyme of the present invention can be obtained by reacting a copolymer with lysozyme.
The ratio when reacting the copolymer with lysozyme cannot be specified unconditionally because it varies depending on the content of amino groups in the lysozyme or acid anhydride groups in the copolymer, but it cannot be specified unconditionally. If the amount of the copolymer is too small, the modification time decreases, and the intended temporal stability becomes insufficient.If the amount of the copolymer is too large, the initial activity of the modified lysozyme is significantly reduced. Is 50 to 400 parts by weight of the copolymer based on 100 parts by weight of lysozyme.
【0018】両者の反応は、共重合体が水溶性の場合
は、リゾチームの水溶液に共重合体を直接添加する方法
がよく、共重合体が水に溶解しにくい場合、あるいは水
に不溶の場合は、共重合体を予め水と相溶性のあるアセ
トン等の溶剤に溶解したのち、リゾチーム水溶液に添加
する方法が容易であり、かつ好ましい方法である。ま
た、反応の際のpHは6〜10、好ましくは8〜9である。
これは、pHが酸性側であるとリゾチーム中の遊離アミノ
基の量が少なくなるので修飾率が低下するためである。The reaction between the two is preferably carried out by directly adding the copolymer to an aqueous solution of lysozyme when the copolymer is water-soluble, and when the copolymer is hardly soluble in water or insoluble in water. Is an easy and preferred method in which a copolymer is dissolved in a solvent such as acetone which is compatible with water in advance and then added to an aqueous lysozyme solution. The pH at the time of the reaction is 6 to 10, preferably 8 to 9.
This is because when the pH is on the acidic side, the amount of free amino groups in lysozyme decreases, and the modification rate decreases.
【0019】また反応温度は、高過ぎると修飾工程での
リゾチームの活性低下がおこり、また、酸無水物基の加
水分解反応がリゾチームのアミノ基と酸無水物基との反
応より起こりやすくなって修飾率が低下するため、0〜
10℃が好ましい範囲である。On the other hand, if the reaction temperature is too high, the activity of lysozyme decreases in the modification step, and the hydrolysis reaction of the acid anhydride group is more likely to occur than the reaction between the amino group and the acid anhydride group of lysozyme. Because the modification rate decreases,
10 ° C. is a preferred range.
【0020】[0020]
【発明の効果】本発明はポリオキシアルキレン基をもつ
アルケニルエーテルと無水マレイン酸との共重合体とリ
ゾチームとの反応生成物である新規な修飾リゾチームで
あり、水系中でも活性を永く持続することができ、且つ
皮膚刺激性が低く適用範囲の広いリゾチームが提供でき
る。Industrial Applicability The present invention is a novel modified lysozyme which is a reaction product of a copolymer of an alkenyl ether having a polyoxyalkylene group with maleic anhydride and lysozyme, and has a long lasting activity even in an aqueous system. It is possible to provide lysozyme having low skin irritation and a wide application range.
【0021】[0021]
【実施例】本発明を製造例および実施例により説明す
る。 製造例1 下記の化合物を1リットルのトルエンに溶解し、窒素雰
囲気下に80±2℃で7時間の重合反応を行った。EXAMPLES The present invention will be described with reference to Production Examples and Examples. Production Example 1 The following compound was dissolved in 1 liter of toluene, and a polymerization reaction was carried out at 80 ± 2 ° C. for 7 hours under a nitrogen atmosphere.
【0022】 CH2=CHCH20(C2H4O)33CH3 1524g (1モ
ル) 無水マレイン酸 103g (1.05モ
ル) 過酸化ベンゾイル 4.8g (0.02モ
ル) 次いでトルエンおよび未反応の無水マレイン酸を10〜30
mmHgの減圧下に100 ±10℃で留去し、1450g の共重合体
No.1を得た。得られた共重合体No.1は淡黄色のワックス
状の固体で、融点は45℃、ケン化価は68.5であった。CH 2 = CHCH 20 (C 2 H 4 O) 33 CH 3 1524 g (1 mol) Maleic anhydride 103 g (1.05 mol) Benzoyl peroxide 4.8 g (0.02 mol) Then toluene and unreacted maleic anhydride 10 to 30
Distillation at 100 ± 10 ° C under reduced pressure of mmHg, 1450g of copolymer
No.1 was obtained. The obtained copolymer No. 1 was a pale yellow waxy solid, having a melting point of 45 ° C. and a saponification value of 68.5.
【0023】製造例2 過酸化ラウロイル19.9g(0.05モル) を1リットルのベン
ゼンに溶解し、窒素雰囲気下に攪拌しながら70℃に昇温
したのち、下記組成の混合液を滴下して70±2℃で重合
反応を行った。 CH2=CHCH20(C2H4O)20C4H9 497g (0.5 モ
ル)Production Example 2 19.9 g (0.05 mol) of lauroyl peroxide was dissolved in 1 liter of benzene and heated to 70 ° C. while stirring under a nitrogen atmosphere. The polymerization reaction was performed at 2 ° C. CH 2 = CHCH 20 (C 2 H 4 O) 20 C 4 H 9 497 g (0.5 mol)
【0024】[0024]
【化3】 Embedded image
【0025】 無水マレイン酸 103g(1.05モ
ル) ベンゼン 3 リットル 全量滴下後、同じ温度で3時間保持したのち、ベンゼン
および未反応の無水マレイン酸を10〜30mmHgの減圧下に
120 ±10℃で留去し、1293g の共重合体No.2を得た。共
重合体No.2は粘稠な液体であり、ケン化価81.5であっ
た。3 g of maleic anhydride 103 g (1.05 mol) After adding 3 liters of benzene in total, the mixture was kept at the same temperature for 3 hours, and then benzene and unreacted maleic anhydride were removed under reduced pressure of 10 to 30 mmHg.
The solvent was distilled off at 120 ± 10 ° C. to obtain 1293 g of copolymer No. 2. Copolymer No. 2 was a viscous liquid and had a saponification value of 81.5.
【0026】以下同様の方法により共重合体No.3〜No.8
を表1〜2に示す反応のモル比及び反応条件で調製し
た。分析値および溶解性を表3に示した。Thereafter, copolymers No. 3 to No. 8 were prepared in the same manner.
Were prepared at the reaction molar ratios and reaction conditions shown in Tables 1-2. The analytical values and solubility are shown in Table 3.
【0027】[0027]
【表1】 [Table 1]
【0028】[0028]
【表2】 [Table 2]
【0029】注1)BPO :ベンゾイルペルオキシド、 LPO :ラウロイルペルオキシド、 tBEH :t−ブチルペルオキシ−2−エチルヘキサノエ
ート、 AIBN :アゾビスイソブチロニトリル、Note 1) BPO: benzoyl peroxide, LPO: lauroyl peroxide, tBEH: t-butylperoxy-2-ethylhexanoate, AIBN: azobisisobutyronitrile,
【0030】[0030]
【表3】 [Table 3]
【0031】実施例 リゾチームとしてニワトリ卵白リゾチームを用い、表1
の共重合体による修飾を試みた。修飾リゾチームの活性
はマイクロコッカス・リソデイクチクス(Micrococcus l
ysodeikticus) 乾燥菌体を用いた下記の測定方法により
測定した。 活性測定法 あらかじめ37℃に保温しておいた基質溶液(注1)3.0m
l に試料溶液(注2)0.1ml を加え攪拌したのち光学セ
ル(1ml)に移し、溶菌に伴う波長640nm における吸光度
の減少を日立分光光度計U−3210で経時的に測定した。
リゾチーム標準品(注3) についても同様に行ない、次
式に従って試料中のリゾチーム量を算出した。Example Using chicken egg white lysozyme as lysozyme, Table 1
The modification with a copolymer was attempted. The activity of the modified lysozyme was determined by the activity of Micrococcus lysodictis (Micrococcus l
ysodeikticus) It was measured by the following measurement method using dried cells. Activity measuring method 3.0m substrate solution (Note 1) pre-incubated at 37 ℃
To this was added 0.1 ml of a sample solution (Note 2), and the mixture was stirred. The mixture was transferred to an optical cell (1 ml), and the decrease in absorbance at a wavelength of 640 nm due to lysis was measured over time using a Hitachi spectrophotometer U-3210.
The same procedure was applied to the standard lysozyme (Note 3), and the amount of lysozyme in the sample was calculated according to the following equation.
【0032】 (注1)マイクロコッカス・リソデイクチクス(M.lysod
eikticus) の乾燥菌体適量に75mMリン酸ナトリウム(pH
6.2) (注4)を加えて振り混ぜ懸濁したのち、同緩衝液
を対照として波長640nm における吸光度が1.00になるよ
うに乾燥菌体または同緩衝液を加える。[0032] (Note 1) Micrococcus lysodetics (M.lysod)
eikticus) to 75 mM sodium phosphate (pH
6.2) Add (Note 4), shake, suspend, and add dry cells or the same buffer so that the absorbance at 640 nm wavelength becomes 1.00 using the same buffer as a control.
【0033】(注2)リゾチーム量が約5〜15μg/g 程
度になるように精製水に溶解する。 (注3)国立衛生試験所標準品 control No.831 (注4)75mM Na2HPO4と75mM NaH2PO4を混合し、pH6.2
に調整する。 実施例1 リゾチーム (力価1.64mg/g)1gをpH8.6 の硼酸系緩衝
液(注5)20gに溶解させ、系の温度を3℃に保持し
た。これに共重合体No.1の1gを微粉末の状態で系に加
えて3±1℃で30分間攪拌したのち、さらに1g加えて
同温度で30分間攪拌を続けた。反応終了後、0.1N−水酸
化ナトリウム水溶液でpHを7.0 に調整した後、逆浸透膜
を用いて無機塩を除去し減圧下35℃で乾燥して修飾リゾ
チーム2.0gを得た。(Note 2) Dissolve in purified water so that the amount of lysozyme is about 5 to 15 μg / g. (Note 3) Standard product of the National Institutes of Health control No.831 (Note 4) 75 mM Na 2 HPO 4 and 75 mM NaH 2 PO 4 are mixed to obtain a pH of 6.2.
Adjust to Example 1 1 g of lysozyme (titer: 1.64 mg / g) was dissolved in 20 g of a boric acid buffer (pH 5) (note 5), and the temperature of the system was kept at 3 ° C. 1 g of Copolymer No. 1 was added to the system in the form of a fine powder, and the mixture was stirred at 3 ± 1 ° C. for 30 minutes. Then, another 1 g was added and stirring was continued at the same temperature for 30 minutes. After the completion of the reaction, the pH was adjusted to 7.0 with a 0.1N aqueous solution of sodium hydroxide, then the inorganic salts were removed using a reverse osmosis membrane, and dried at 35 ° C under reduced pressure to obtain 2.0 g of modified lysozyme.
【0034】得られた修飾リゾチームの活性を測定した
結果は0.41mg/gであり、リゾチームの修飾による活性残
存率は純分換算で75%であった。 (注5)硼酸系緩衝液(pH8.6) 0.2M−水酸化ナトリウム水溶液 12.00ml 0.2M−硼酸・塩化カリウム水溶液 50.00ml 上記水溶液を混合し、精製水を加えて全量を200ml にし
たもの。The result of measuring the activity of the obtained modified lysozyme was 0.41 mg / g, and the residual activity ratio by the modification of lysozyme was 75% in terms of a pure content. (Note 5) Boric acid buffer (pH 8.6) 0.2M-sodium hydroxide aqueous solution 12.00ml 0.2M-boric acid / potassium chloride aqueous solution 50.00ml The above aqueous solutions were mixed, and purified water was added to make a total volume of 200ml.
【0035】なお、0.2M−硼酸・塩化カリウム水溶液
は、溶液1リットル中に硼酸12.4g と塩化カリウム14.9
g を含む水溶液である。修飾リゾチームおよび原料のリ
ゾチームの赤外線吸収スペクトル図をそれぞれ図1及び
図2に示す。The aqueous solution of 0.2 M boric acid / potassium chloride is composed of 12.4 g of boric acid and 14.9 g of potassium chloride per liter of solution.
It is an aqueous solution containing g. FIGS. 1 and 2 show the infrared absorption spectra of the modified lysozyme and the raw material lysozyme, respectively.
【0036】また、これらのゲルパーミュエーションク
ロマトグラムを、共重合体No.1とともに図3に示すが、
この図から修飾リゾチームの分子量が高分子量化してい
ることがわかる。なお、ゲルパーミュエーションクロマ
トグラフィーの条件は次の通りである。 FIG. 3 shows these gel permeation chromatograms together with copolymer No. 1.
From this figure, it can be seen that the molecular weight of the modified lysozyme has increased. The conditions for gel permeation chromatography are as follows.
【0037】試料濃度 :リゾチーム 0.5mg/ml 修飾リゾチーム 1.0mg/ml 試料注入量: 100μl 溶媒 :0.1M燐酸系緩衝液(pH7.0) 流速 :0.5ml/分 検出器 :昭和電工(株)RI示差屈計SE−61 実施例2 リゾチーム (力価1.64mg/g) 1gを pH8.0の燐酸系緩衝
液(注6)20gに溶解させ、温度を3℃に保持した。こ
れに共重合体No.3の 0.5g(20%アセトン溶液)を加えて
3±1℃で30分間攪拌し、さらに0.5g(20%アセトン溶
液)を加えて同温度で30分間攪拌した。Sample concentration: 0.5 mg / ml lysozyme 1.0 mg / ml modified lysozyme Sample injection volume: 100 μl Solvent: 0.1 M phosphate buffer (pH 7.0) Flow rate: 0.5 ml / min Detector: RI, Showa Denko KK Example 2 1 g of lysozyme (titer: 1.64 mg / g) was dissolved in 20 g of a pH 8.0 phosphate buffer (Note 6), and the temperature was kept at 3 ° C. To this, 0.5 g (20% acetone solution) of Copolymer No. 3 was added, and the mixture was stirred at 3 ± 1 ° C. for 30 minutes. Further, 0.5 g (20% acetone solution) was added, and the mixture was stirred at the same temperature for 30 minutes.
【0038】次に、減圧下に35℃で水分を留去し、修飾
リゾチームを2.1g得た。得られた修飾リゾチームの活性
は0.435mg/g であり、修飾による活性残存率は純分換算
で63%であった。 (注6)燐酸系緩衝液(pH8.0) 0.2M−水酸化ナトリウム水溶液 46.85ml 0.2M−燐酸二水素カリウム水溶液 50.00ml 上記水溶液を混合し、精製水を加えて全量を200ml にし
たもの。Next, water was distilled off at 35 ° C. under reduced pressure to obtain 2.1 g of modified lysozyme. The activity of the resulting modified lysozyme was 0.435 mg / g, and the residual activity by modification was 63% in pure content. (Note 6) Phosphate buffer (pH 8.0) 0.2M-aqueous sodium hydroxide solution 46.85ml 0.2M-potassium dihydrogen phosphate aqueous solution 50.00ml The above aqueous solutions were mixed, and purified water was added to make a total volume of 200ml.
【0039】実施例3〜7および比較例1〜2 以下、同様の方法で表4に示す修飾リゾチームを得た。
なお、実施例3、4、5、6は実施例1と同様に逆浸透
膜を用いて無機塩を除去した。これらの修飾リゾチーム
の活性および経時安定性テストの結果を表4に示す。Examples 3 to 7 and Comparative Examples 1 and 2 Modified lysozyme shown in Table 4 was obtained in the same manner as described below.
In Examples 3, 4, 5, and 6, inorganic salts were removed using a reverse osmosis membrane as in Example 1. Table 4 shows the results of the activity and the stability over time of these modified lysozymes.
【0040】経時安定性テスト 修飾リゾチーム0.5gをpH7.0 の燐酸系緩衝液(注7)10
0ml(防腐剤として4−ヒドロキシ安息香酸メチル 0.1%
含有)に溶解し、40℃に所定時間保持し、修飾リゾチー
ムの活性を測定して経時安定性を調べた。比較液とし
て、リゾチーム0.15g をpH7.0 の燐酸系緩衝液100ml(防
腐剤として4−ヒドロキシ安息香酸メチル0.1 %含有)
に溶解したもの(比較例1)と、これにソルビトールを
30%添加したもの(比較例2)についても経時安定性を
調べた。Stability test with time 0.5 g of modified lysozyme was added to a phosphate buffer (pH 7) of pH 7.0 (Note 7).
0ml (Methyl 4-hydroxybenzoate 0.1% as preservative
Was maintained at 40 ° C. for a predetermined time, and the activity of the modified lysozyme was measured to examine the stability over time. As a comparative solution, 0.15 g of lysozyme was added to 100 ml of a phosphate buffer at pH 7.0 (containing 0.1% of methyl 4-hydroxybenzoate as a preservative).
(Comparative Example 1) and sorbitol
The stability with time was also examined for the one to which 30% was added (Comparative Example 2).
【0041】表4より、本発明の修飾リゾチームが水系
中において優れた経時安定性をもっていることがわか
る。 (注7)燐酸系緩衝液(pH7.0) 10mM燐酸水素2ナトリウム水溶液と10mM燐酸水素1ナト
リウム水溶液を混合してpHを7.0 に調整したもの。Table 4 shows that the modified lysozyme of the present invention has excellent temporal stability in an aqueous system. (Note 7) Phosphate buffer (pH 7.0) pH adjusted to 7.0 by mixing 10 mM disodium hydrogen phosphate aqueous solution and 10 mM monosodium hydrogen phosphate aqueous solution.
【0042】[0042]
【表4】 [Table 4]
【0043】注1)単位:mg/g 2)リゾチームの活性(力価 1.64mg/g) に対する修
飾リゾチーム活性率(%) 3)修飾リゾチームの初期活性に対する活性率(%) 4)リゾチームを燐酸系緩衝液(4−ヒドロキシ安息香
酸メチル含有)に溶解したもの 5)リゾチーム水溶液にソルビトールを30%添加したも
の。Note 1) Unit: mg / g 2) Modified lysozyme activity rate (%) relative to lysozyme activity (titer 1.64 mg / g) 3) Activity rate (%) relative to initial activity of modified lysozyme 4) Phosphoric acid Dissolved in a system buffer (containing methyl 4-hydroxybenzoate) 5) A solution obtained by adding 30% of sorbitol to an aqueous lysozyme solution.
【図1】共重合体No.1で修飾されたリゾチームの赤外線
吸収スペクトル図である。FIG. 1 is an infrared absorption spectrum of lysozyme modified with copolymer No. 1.
【図2】リゾチームの赤外線吸収スペクトル図である。FIG. 2 is an infrared absorption spectrum diagram of lysozyme.
【図3】リゾチーム、共重合体No.1および修飾リゾチー
ムのゲルパーミュエーションクロマトグラムである。FIG. 3 is a gel permeation chromatogram of lysozyme, copolymer No. 1 and modified lysozyme.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI A61P 31/12 A61P 35/00 35/00 43/00 43/00 A61K 37/54 (72)発明者 足立 佳津良 東京都北区栄町48番18号 株式会社コー セー研究所内 (72)発明者 安河内 徹 神奈川県川崎市川崎区藤崎2−3−10− 404 (72)発明者 杉中 昭典 神奈川県茅ヶ崎市室田2−4−10 (56)参考文献 特開 平1−153088(JP,A) 特開 平1−165377(JP,A) 特公 昭55−10235(JP,B1) (58)調査した分野(Int.Cl.7,DB名) C12N 9/00 - 9/99 A61K 31/00 - 48/00 A61P 1/00 - 43/00 BIOSIS(DIALOG) CA(STN) MEDLINE(STN) REGISTRY(STN) WPI(DIALOG)──────────────────────────────────────────────────続 き Continuation of the front page (51) Int.Cl. 7 Identification code FI A61P 31/12 A61P 35/00 35/00 43/00 43/00 A61K 37/54 (72) Inventor Yoshiura Adachi Kita, Tokyo 48-18 Sakaemachi-ku, Kose Research Institute Co., Ltd. (72) Inventor Tohru Yasugouchi 2-3-10-, Fujisaki, Kawasaki-ku, Kawasaki-shi, Kanagawa 404 10 (56) References JP-A 1-153088 (JP, A) JP-A 1-165377 (JP, A) JP-B 55-10235 (JP, B1) (58) Fields investigated (Int. Cl. 7 , DB name) C12N 9/00-9/99 A61K 31/00-48/00 A61P 1/00-43/00 BIOSIS (DIALOG) CA (STN) MEDLINE (STN) REGISTRY (STN) WPI (DIALOG)
Claims (1)
と無水マレイン酸と他の単量体とのモル比が、5〜60:
20〜90:0〜30である共重合体で修飾されたリゾチー
ム。 【化1】 (Zは2〜8個の水酸基を持つ化合物の残基、AOは炭
素数2〜18のオキシアルキレン基の1種または2種以上
の混合物で、2種以上のときはブロック状に付加してい
てもランダム状に付加していてもよく、R1 は炭素数2
〜5のアルケニル基、R2 は炭素数1〜24の炭化水素基
またはアシル基、aとbとcはオキシアルキレン基の平
均付加モル数でそれぞれ0〜600 、mは1〜7の整数、
nは0〜6の整数、m+n=1〜7、n/(1+m+
n)≦1/2、かつa+bm+cn=1〜1000であ
る。)The molar ratio of the alkenyl ether represented by the formula (1), maleic anhydride and another monomer is 5 to 60:
Lysozyme modified with a copolymer of 20-90: 0-30. Embedded image (Z is a residue of a compound having 2 to 8 hydroxyl groups, AO is one or a mixture of two or more oxyalkylene groups having 2 to 18 carbon atoms, and if two or more, it is added in a block form. R 1 may have 2 carbon atoms.
An alkenyl group of 5 to 5, R 2 is a hydrocarbon group or an acyl group having 1 to 24 carbon atoms, a, b and c are each an average addition mole number of an oxyalkylene group of 0 to 600, m is an integer of 1 to 7,
n is an integer of 0 to 6, m + n = 1 to 7, n / (1 + m +
n) ≦ 1 / and a + bm + cn = 1 to 1000. )
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP04157391A JP3106265B2 (en) | 1992-05-26 | 1992-05-26 | Modified lysozyme |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP04157391A JP3106265B2 (en) | 1992-05-26 | 1992-05-26 | Modified lysozyme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05328971A JPH05328971A (en) | 1993-12-14 |
| JP3106265B2 true JP3106265B2 (en) | 2000-11-06 |
Family
ID=15648613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP04157391A Expired - Fee Related JP3106265B2 (en) | 1992-05-26 | 1992-05-26 | Modified lysozyme |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3106265B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7811556B2 (en) | 2003-03-24 | 2010-10-12 | Sankyo Company, Limited | Polymeric modifiers and pharmaceutical compositions |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11253156A (en) * | 1997-12-25 | 1999-09-21 | Mitsubishi Gas Chem Co Inc | Modified catalase, modified catalase composition and method for producing modified catalase |
| EP2552998A4 (en) * | 2010-03-30 | 2013-11-06 | Spago Imaging Ab | COMPACT RAMIFIED POLYETHYLENE GLYCOL DERIVATIVES |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1155793A (en) * | 1967-05-09 | 1969-06-18 | Prodotti Antibiotici Spa | Process for the Recovery and Purification of Lysozyme |
| IT1223122B (en) * | 1987-11-13 | 1990-09-12 | Unibios Spa | HIGHLY BIOAVAILABLE AND TOLERABLE PROTEIN IRON DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
| JPH01153088A (en) * | 1987-12-09 | 1989-06-15 | Mihama Hisaharu | Modified enzyme |
-
1992
- 1992-05-26 JP JP04157391A patent/JP3106265B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7811556B2 (en) | 2003-03-24 | 2010-10-12 | Sankyo Company, Limited | Polymeric modifiers and pharmaceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05328971A (en) | 1993-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5576012A (en) | Pharmaceutical aqueous formulations containing a sparingly soluble pharmaceutical active compound with a solubilizing polymeric agent | |
| EP0282951B1 (en) | Controlled release preparations of active materials | |
| US5770627A (en) | Hydrophobically-modified bioadhesive polyelectrolytes and methods relating thereto | |
| US7205380B2 (en) | Sterically hindered poly (ethylene glycol) alkanoic acids and derivatives thereof | |
| HUT71586A (en) | Process for producing lyp0philized polyalkyene oxide modified protein and polypeptide complexes with cyclodextrin | |
| Kaplan et al. | Development and characterization of gels and liposomes containing ovalbumin for nasal delivery | |
| JP2978187B2 (en) | Method for producing modified superoxide dismutase | |
| JP3106265B2 (en) | Modified lysozyme | |
| US4906715A (en) | N,N'-divinylalkylurea crosslinked polymers, a process for their preparation, and their use | |
| JP2000355614A (en) | Carboxylated polymer composition | |
| WO2024130622A1 (en) | Composition for caring for and/or making up keratin materials | |
| JP3035675B2 (en) | Modified superoxide dismutase | |
| JP3236970B2 (en) | Cosmetics | |
| JP3271265B2 (en) | Modified protease | |
| JP3000488B2 (en) | Cosmetics | |
| JP3057459B2 (en) | Cosmetics | |
| EP0931831B1 (en) | Modified catalase, a composition thereof and process for preparing the catalase | |
| CA2253737A1 (en) | Micellar aqueous composition and method for solubilizing hydrophobic drug | |
| EP0045285A1 (en) | Non absorbable compounds of mucolytic activity, the process for their preparation and therapeutic compositions which contain them as active principle | |
| JP2803265B2 (en) | Denatured polypeptide and use thereof | |
| JP3505591B2 (en) | Enzyme stabilizer | |
| JPH06141857A (en) | Modified gamma-gultamyltranspeptidase and its use | |
| JP3395011B2 (en) | Cosmetic or pharmaceutical additives | |
| JP3428044B2 (en) | Reactive liposomes and forming agents | |
| JPH11253156A (en) | Modified catalase, modified catalase composition and method for producing modified catalase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |